Cargando…

Emerging concepts in heart failure management and treatment: focus on vericiguat

The nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) pathway is dysregulated in patients with heart failure (HF) resulting in myocardial and vascular dysfunction that contributes to its progression. Vericiguat is a novel direct sGC stimulator that targets in at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaplinsky, Edgardo, Perrone, Sergio, Barbagelata, Alejandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828868/ https://www.ncbi.nlm.nih.gov/pubmed/36660012 http://dx.doi.org/10.7573/dic.2022-5-5

Ejemplares similares

Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy
por: Báez Cabanillas, María Victoria, et al.
Publicado: (2023)

Emerging concepts in heart failure management and treatment: focus on point-of-care ultrasound in cardiogenic shock
por: Ruben, Mariela, et al.
Publicado: (2023)

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction
por: Ospina González, Oscar Eduardo, et al.
Publicado: (2023)

Emerging concepts in heart failure management and treatment: circulatory support with extracorporeal membrane oxygenation (ECMO)
por: Swedzky, Federico, et al.
Publicado: (2023)

Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023)

Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
por: Kaplinsky, Edgardo, et al.
Publicado: (2018)

Vericiguat: A New Hope for Heart Failure Patients
por: Chiles, Raquel, et al.
Publicado: (2022)

Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination
por: Kaplinsky, Edgardo
Publicado: (2016)

Chronic heart failure: the role of di vericiguat
por: Caminiti, Giuseppe, et al.
Publicado: (2023)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
por: Falco, Luigi, et al.
Publicado: (2023)

A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure
por: Sahana, Urjosee, et al.
Publicado: (2023)

Vericiguat in Heart Failure: Characteristics, Scientific Evidence and Potential Clinical Applications
por: Vannuccini, Francesca, et al.
Publicado: (2022)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?
por: Kaplinsky, Edgardo
Publicado: (2015)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
por: Kaplinsky, Edgardo
Publicado: (2020)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Efficacy and safety of vericiguat in heart failure: a meta-analysis
por: Ma, Jianhua, et al.
Publicado: (2023)

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
por: Nakamura, Makiko, et al.
Publicado: (2023)

Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?
por: Hammer, Andreas, et al.
Publicado: (2023)

After having changed the treatment of heart failure with reduced ejection fraction: what are the latest evidences with sacubitril valsartan?
por: Kaplinsky, Edgardo
Publicado: (2019)

Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations
por: Kassis-George, Hayah, et al.
Publicado: (2022)

Dengue Myocarditis: A Case Report and Major Review
por: Cristodulo, Roberto, et al.
Publicado: (2023)

The efficacy of vericiguat for heart failure: A meta-analysis of randomized controlled trials
por: Ma, Guofang, et al.
Publicado: (2023)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

ANMCO position paper on vericiguat use in heart failure: from evidence to place in therapy
por: Di Fusco, Stefania Angela, et al.
Publicado: (2023)

Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
por: Voors, Adriaan A., et al.
Publicado: (2021)

Dosing Challenges and Benefits of Vericiguat in a Patient With Decompensated Heart Failure: A Case Report
por: Speranza-Sánchez, Mario, et al.
Publicado: (2023)

Sacubitril/valsartan, sodium‐glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy
por: Norre, Tobias, et al.
Publicado: (2022)

Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event
por: Alsumali, Adnan, et al.
Publicado: (2021)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
por: Alsumali, Adnan, et al.
Publicado: (2021)

Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
por: Gandjour, Afschin
Publicado: (2022)

Renal protection in chronic heart failure: focus on sacubitril/valsartan
por: Pontremoli, Roberto, et al.
Publicado: (2021)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Targets and management of hypertension in heart failure: focusing on the stages of heart failure
por: Miao, Huanhuan, et al.
Publicado: (2022)

The clinical development of sGC modulators, riociguat and vericiguat
por: Misselwitz, Frank
Publicado: (2015)

Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
por: Gopal, Muralikrishna, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_47tsgfr9gr8rsfok5qdfleq7tr